One plan - full access

No subscription, no auto-renewal, no hidden terms.
Pay once and use it for 30 days.

PRO plan No auto-renewal
$18

30 days of full access
One-time payment

🌐 US & Global Companies
Get access for 30 days →
♧ Secure payment · Instant access

What is included

  • ✓Full access to detailed company analysis
  • ✓Fundamental screener
  • ✓Advanced stock screener filters
  • ✓5 ratings. Separate lists for US & Global Companies and MOEX
  • ✓Company data export in XLSX and CSV
  • ✓MarketCap’s overall ranking of top companies
  • ✓Analytics updates after each new financial report
⚠ The service is not an investment advisor. Financial statement data from public companies is available to everyone - MarketCap structures and analyzes it.
Seagen  logo
Seagen SGEN
report update icon

Quarterly report 2023-Q3
added 05-16-2026

Seagen Income Statement 2022-2008 | SGEN

Brief overview of revenue and earnings at Seagen

The comparison covers a five-year financial horizon. According to figures from Seagen, revenue changed from $130 million to $2 billion over five years. Across the full period, sales moved by +1414.1%; the average annual rate was 72.2%. This pace points to rapid expansion of the business.

Gross profit was $428 million at the start and $1.6 billion at the end of the period (+262.6%). Gross profit as a share of revenue changed from 330.3% to 79.1%. The contraction points to pressure from direct costs or weaker pricing power.

EBITDA was −172 million dollars at the beginning and −566 million dollars at the end of the period (−230.1%). EBITDA lagged revenue, showing weaker operating momentum. At the operating-margin level, the figure shifted from −132.3% to −28.9%. The company improved its ability to convert sales into EBITDA.

The net financial result changed from −126 million dollars to −610 million dollars. Profitability deteriorated further over the five years.

The market value of the business moved from $7.7 billion to $26.3 billion, or +240.2%. Market value lagged the financial performance.

Summary assessment

The current trajectory does not yet confirm a sustainable recovery. The positive side is supported by higher operating efficiency and sales growth. The most visible risks are lower net income, limited operating profitability and weaker gross profitability. The next reporting periods will show whether revenue, margins, and final profitability can strengthen.

Annual Income Statement Seagen

2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 2008

Market Cap

26.3 B 23.5 B 26.4 B 18.8 B 11.7 B 7.73 B 9.24 B 3.9 B 4.47 B 6.39 B 3.32 B 2.09 B - - -

Shares

185 M 182 M 175 M 165 M 158 M 143 M 141 M 129 M 123 M 122 M 118 M 113 M 101 M - -

Historical Prices

142 129 151 114 74.3 54 65.7 30.2 36.2 52.6 28.1 18.5 - - -

Net Income

-610 M -674 M 614 M -159 M -223 M -126 M -140 M -120 M -76.1 M -62.5 M -53.8 M -152 M -66.3 M -81.7 M -

Revenue

1.96 B 1.57 B 2.18 B 917 M 655 M 130 M 105 M 337 M 287 M 269 M 211 M 94.8 M 107 M 52 M -

Cost of Revenue

410 M 312 M 218 M 44 M 88.3 M - - - - - - - - - -

Gross Profit

- - - 873 M 566 M 428 M 376 M 299 M 258 M 248 M 197 M 91.7 M - - -

Operating Income

-613 M -682 M 597 M -221 M -260 M -196 M -143 M -121 M -77.4 M -62.9 M -57.3 M -144 M -68.2 M -84.9 M -

EBITDA

-566 M -639 M 633 M -197 M -234 M -172 M -125 M -106 M -64.9 M -54.2 M -51.1 M -140 M -64.6 M -81.6 M -

Operating Expenses

- - - 1.09 B 826 M 624 M 519 M 420 M 335 M 311 M 255 M 236 M - - -

General and Administrative Expenses

821 M 716 M 534 M 374 M 261 M 167 M 139 M 126 M 104 M 92.4 M 84.3 M 72.7 M 29.3 M 17.7 M -

All numbers in USD currency

Quarterly Income Statement Seagen

2023-Q3 2023-Q2 2023-Q1 2022-Q4 2022-Q3 2022-Q2 2022-Q1 2021-Q4 2021-Q3 2021-Q2 2021-Q1 2020-Q4 2020-Q3 2020-Q2 2020-Q1 2019-Q4 2019-Q3 2019-Q2 2019-Q1 2018-Q4 2018-Q3 2018-Q2 2018-Q1 2017-Q4 2017-Q3 2017-Q2 2017-Q1 2016-Q4 2016-Q3 2016-Q2 2016-Q1 2015-Q4 2015-Q3 2015-Q2 2015-Q1 2014-Q4 2014-Q3 2014-Q2 2014-Q1 2013-Q4 2013-Q3 2013-Q2 2013-Q1 2012-Q4 2012-Q3 2012-Q2 2012-Q1 2011-Q4 2011-Q3 2011-Q2 2011-Q1

Shares

188 M 188 M 187 M 187 M 185 M 184 M 184 M 183 M 182 M 182 M 181 M 181 M 174 M 173 M 172 M 172 M 168 M 161 M 161 M 160 M 159 M 158 M 152 M 144 M 143 M 143 M 142 M 142 M 141 M 140 M 140 M 140 M 128 M 125 M 124 M 124 M 124 M 123 M 123 M 123 M 122 M 121 M 120 M 120 M 118 M 117 M 117 M 116 M 115 M 114 M 109 M

Net Income

-216 M -212 M -175 M - -191 M -135 M -136 M - -294 M -84.6 M -121 M 167 M 636 M -21.2 M -168 M 25.8 M -91.9 M -79.2 M -13.3 M -120 M -67.4 M 76.3 M -112 M -59.2 M 50 M -56.4 M -60 M -55.1 M -31.8 M -32.7 M -20.5 M -24.9 M -26.4 M -47.5 M -21.7 M -26.7 M -15.6 M -17.6 M -16.3 M -15.7 M -23.7 M -6.9 M -16.3 M -10.6 M -13.7 M -17.2 M -12.3 M -27.2 M -40.7 M -51.5 M -32.7 M

Revenue

649 M 604 M 520 M - 510 M 498 M 426 M - 424 M 388 M 332 M 601 M 1.06 B 278 M 235 M 290 M 213 M 218 M 195 M 175 M 169 M 170 M 141 M 130 M 135 M 108 M 109 M 105 M 106 M 95.4 M 111 M 93.5 M 84.1 M 77.1 M 82.2 M 74.3 M 75.9 M 68.3 M 68.3 M 67.4 M 71 M 73.6 M 57.3 M 63.9 M 49.8 M 48.8 M 48.2 M 48.9 M 20.7 M 13.1 M 12.2 M

Cost of Revenue

165 M 181 M 112 M - 108 M 106 M 87.6 M - 82.6 M 78.1 M 64.1 M - 78.3 M 48.2 M 29.4 M - 10.8 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Operating Income

-231 M -221 M -185 M - -193 M -133 M -133 M - -298 M -89.6 M -122 M - 638 M -94 M -112 M - -89.8 M -38.7 M -53.6 M - -45.6 M -30.3 M -93.8 M - -32.2 M -59.3 M -59.3 M - -32.4 M -33.4 M -21 M - -26.5 M -47.6 M -21.7 M - -15.6 M -17.6 M -16.4 M - -23.8 M -7.01 M -16.4 M - -13.8 M -17.3 M -15.5 M - -40.9 M -51.8 M -33 M

EBITDA

-193 M -196 M -172 M - -158 M -110 M -122 M - -268 M -70 M -113 M - 664 M -77.4 M -106 M - -75.6 M -28.8 M -48.7 M - -26.5 M -16.5 M -86.8 M - -15.8 M -49.1 M -54.5 M - -19.1 M -24.8 M -16.8 M - -15.7 M -40.5 M -18.3 M - -6.52 M -11.7 M -13.5 M - -17.7 M -3.17 M -14.7 M - -9.2 M -14.3 M -14 M - -38.2 M -50 M -32.1 M

Operating Expenses

- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - 64.8 M 45.1 M

General and Administrative Expenses

266 M 244 M 236 M - 210 M 220 M 174 M - 180 M 165 M 160 M - 128 M 126 M 122 M - 96.1 M 82.3 M 80.3 M - 57.2 M 58.3 M 66.2 M - 39.7 M 40.7 M 38.4 M - 34.8 M 33.3 M 29.7 M - 29.7 M 30.3 M 32.1 M - 25.3 M 25.5 M 24 M - 21.5 M 23.5 M 21.9 M - 18.8 M 19.9 M 22.2 M - 19.8 M 15.2 M 12.7 M

All numbers in USD currency

The income statement is one of the three key financial reports of a company Seagen (alongside the balance sheet and the cash flow statement). It shows how the company makes money and what its expenses are:

  • How much revenue the company earned
  • How much it spent on production, personnel, marketing, taxes, etc.
  • What profit remained in the end

Analyzing the income statement helps an investor understand whether the business generates stable and growing profits, how effectively the company controls its expenses, and whether it is capable of generating income in the future. Additionally, this analysis shows how the company copes with crises and economic cycles, and allows assessing the potential for stock price growth and dividend payments.

Features
  • The income statement may include both recurring and one-time items (for example, profit from the sale of assets). It is necessary to separate core metrics from one-off events for accurate analysis.
  • Companies often publish interim reports (e.g., quarterly), which allows for more timely tracking of trends.
  • A combined analysis of the income statement with the balance sheet and cash flow statement provides a comprehensive view of the company’s financial health.

Reports on the profits and losses of other stocks in the Biotechnology industry

Issuer Price % 24h Market Cap Country
Edesa Biotech Edesa Biotech
EDSA
$ 2.19 2.67 % $ 12.4 M usaUSA
Bristol-Myers Squibb Company Bristol-Myers Squibb Company
BMY
$ 62.15 -1.6 % $ 126 B usaUSA
Biohaven Pharmaceutical Holding Company Ltd. Biohaven Pharmaceutical Holding Company Ltd.
BHVN
$ 14.49 4.4 % $ 937 M usaUSA
Moderna Moderna
MRNA
$ 253.93 5.17 % $ 98.8 B usaUSA
XTL Biopharmaceuticals Ltd. XTL Biopharmaceuticals Ltd.
XTLB
$ 1.55 -9.36 % $ 1.04 B israelIsrael
Achieve Life Sciences Achieve Life Sciences
ACHV
$ 6.75 5.8 % $ 294 M usaUSA
Amgen Amgen
AMGN
$ 460.27 0.28 % $ 248 B usaUSA
Armata Pharmaceuticals Armata Pharmaceuticals
ARMP
$ 3.37 12.33 % $ 122 M usaUSA
Axsome Therapeutics Axsome Therapeutics
AXSM
$ 132.34 1.95 % $ 6.58 B usaUSA
Champions Oncology Champions Oncology
CSBR
$ 4.8 0.85 % $ 66.4 M usaUSA
Forte Biosciences Forte Biosciences
FBRX
$ 76.99 0.03 % $ 997 M usaUSA
Immunic Immunic
IMUX
$ 7.79 6.42 % $ 1.21 B usaUSA
AC Immune SA AC Immune SA
ACIU
$ 2.23 5.69 % $ 225 M schweizSchweiz
Aldeyra Therapeutics Aldeyra Therapeutics
ALDX
$ 0.64 4.12 % $ 38.4 M usaUSA
Aptose Biosciences Aptose Biosciences
APTO
- -45.71 % $ 1.2 M canadaCanada
Precision BioSciences Precision BioSciences
DTIL
$ 10.62 7.6 % $ 136 M usaUSA
AIM ImmunoTech AIM ImmunoTech
AIM
$ 0.16 4.41 % $ 259 K usaUSA
Ascendis Pharma A/S Ascendis Pharma A/S
ASND
$ 256.91 1.37 % $ 15.6 B danmarkDanmark
ANI Pharmaceuticals ANI Pharmaceuticals
ANIP
$ 67.32 -3.3 % $ 1.35 B usaUSA
Actinium Pharmaceuticals Actinium Pharmaceuticals
ATNM
$ 1.42 9.23 % $ 44.3 M usaUSA
Autolus Therapeutics plc Autolus Therapeutics plc
AUTL
$ 1.29 2.38 % $ 343 M britainBritain
BridgeBio Pharma BridgeBio Pharma
BBIO
$ 74.28 0.01 % $ 14.2 B usaUSA
BioCryst Pharmaceuticals BioCryst Pharmaceuticals
BCRX
$ 7.69 0.72 % $ 1.61 B usaUSA
Bicycle Therapeutics plc Bicycle Therapeutics plc
BCYC
$ 3.6 3.45 % $ 249 M britainBritain
Coherus BioSciences Coherus BioSciences
CHRS
$ 0.77 2.9 % $ 90.2 M usaUSA
Arcutis Biotherapeutics Arcutis Biotherapeutics
ARQT
$ 25.59 -5.24 % $ 3.26 B usaUSA
Cellectis S.A. Cellectis S.A.
CLLS
$ 1.09 5.83 % $ 109 M franceFrance
BeyondSpring BeyondSpring
BYSI
$ 0.61 -3.32 % $ 25.1 M usaUSA
Alkermes plc Alkermes plc
ALKS
$ 45.88 3.01 % $ 7.56 B irlandaIrlanda
Altimmune Altimmune
ALT
$ 2.09 6.09 % $ 184 M usaUSA
Cardiff Oncology Cardiff Oncology
CRDF
$ 0.8 5.3 % $ 53.5 M usaUSA
Citius Pharmaceuticals Citius Pharmaceuticals
CTXR
$ 0.55 -1.2 % $ 6.09 M usaUSA
Arcturus Therapeutics Holdings Arcturus Therapeutics Holdings
ARCT
$ 10.35 10.52 % $ 283 M israelIsrael
Arrowhead Pharmaceuticals Arrowhead Pharmaceuticals
ARWR
$ 58.16 1.22 % $ 7.78 B usaUSA
Incyte Corporation Incyte Corporation
INCY
$ 119.79 1.51 % $ 23.4 B usaUSA
Atara Biotherapeutics Atara Biotherapeutics
ATRA
$ 7.81 -1.88 % $ 98 M usaUSA
Aurinia Pharmaceuticals Aurinia Pharmaceuticals
AUPH
$ 16.32 0.68 % $ 2.19 B canadaCanada
Cullinan Management Cullinan Management
CGEM
$ 11.37 5.28 % $ 685 M usaUSA
BioNTech SE BioNTech SE
BNTX
$ 87.46 1.86 % $ 21.1 B germanyGermany
Collegium Pharmaceutical Collegium Pharmaceutical
COLL
$ 24.19 -3.86 % $ 766 M usaUSA
Corbus Pharmaceuticals Holdings Corbus Pharmaceuticals Holdings
CRBP
$ 3.07 7.34 % $ 40.9 M usaUSA
Enlivex Therapeutics Ltd. Enlivex Therapeutics Ltd.
ENLV
$ 1.26 -0.79 % $ 57.6 M israelIsrael
AnaptysBio AnaptysBio
ANAB
$ 46.46 1.92 % $ 1.35 B usaUSA
Assembly Biosciences Assembly Biosciences
ASMB
$ 20.43 2.17 % $ 229 M usaUSA
Adagene Adagene
ADAG
$ 1.99 -1.73 % $ 117 M chinaChina
Benitec Biopharma Benitec Biopharma
BNTC
$ 9.51 10.07 % $ 443 M usaUSA
Denali Therapeutics Denali Therapeutics
DNLI
$ 20.09 1.88 % $ 3.47 B usaUSA
Amarin Corporation plc Amarin Corporation plc
AMRN
$ 11.55 -0.2 % $ 4.79 B irlandaIrlanda
Editas Medicine Editas Medicine
EDIT
$ 2.57 0.59 % $ 228 M usaUSA
Agios Pharmaceuticals Agios Pharmaceuticals
AGIO
$ 29.4 4.0 % $ 1.7 B usaUSA